Small molecule inhibitors for the treatment of signal kinases will cause changes in drug targets, for example, certain lung cancer patients with EGFR mutations developed resistance to EGFR inhibitors within one year, and EGFR-T790M gatekeeper mutation was reported in half of the cases (Bell et al., 2005). This evidence concerns the gene EGFR and lung cancer.